Skip to main content
Premium Trial:

Request an Annual Quote

The Line in the Sand Over Personalized Medicine Is Drawn

Warfarin will soon have a label saying that people with certain genetic variations should start off with a lower initial dose of the blood thinner, reports the Wall Street Journal. Adding this label is part of the Food and Drug Administration's push to promote using genetics to predict patient's reactions to medicine, a major tenet of personalized medicine. This stance, though, is pitting the FDA against major insurers in the US that do not cover the tests.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.